Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial. - Peccatori N; Locatelli F; Ammerlaan ACJ; Jiang Y; van der Velden VHJ; Lissat A; Nilsson A; Bielorai B; Moerloose B; Rives S; Rubio-San-Simon A; Dirksen U; et al. (The Lancet. Haematology, 2026)